IDiyas

For the Inventor, By the Inventor

Menlo Park, CA, United States of America

Deborah A Eppstein

USPTO Granted Patents = 15

Average Co-Inventor Count = 2.9

ph-index = 13

Forward Citations = 3,223(Granted Patents)


Location History:

  • Los Altos, CA (US) (1985 - 1989)
  • Menlo Park, CA (US) (1990 - 1997)
  • Palo Alto, CA (US) (1987 - 2002)

Company Filing History:

goldMedal14 out of 932 
 
Syntex (u.s.a.) Inc.
 patents
silverMedal1 out of 832,680 
Other
 patents

Years Active: 1985-2002

Loading Chart...
15 patents (USPTO):Explore Patents
1. 6387395 - N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor (2002-05-14),
2. 5783179 - C-reactive protein fragment with immunomodulatory activity (1998-07-21),
3. 5622712 - N-[.omega., (.omega.-1)-dialkyloxy]- and N-[.omega., (1997-04-22),
4. 5550289 - N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy (1996-08-27),
5. 5545412 - N-[1, (1-1)-dialkyloxy]-and N-[1, (1996-08-13),
6. 5366737 - N-[.omega.,(.omega.-1)-dialkyloxy]- and (1994-11-22),
7. 5208036 - N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (1993-05-04),
8. 5049386 - N-.omega.,(.omega.-1)-dialkyloxy)- and (1991-09-17),
9. 4962091 - Controlled release of macromolecular polypeptides (1990-10-09),
10. 4946787 - N-(.omega.,(.omega.-1)-dialkyloxy)- and (1990-08-07),
11. 4897355 - N[.omega.,(.omega.-1)-dialkyloxy]- and (1990-01-30),
12. 4857316 - Synergistic antiviral composition (1989-08-15),
13. 4684625 - Method for enhancing the anti-infective activity of muramyldipeptide (1987-08-04),
14. 4606917 - Synergistic antiviral composition (1986-08-19),
15. 4522811 - Serial injection of muramyldipeptides and liposomes enhances the (1985-06-11),

Title: **Deborah A. Eppstein: Innovator in Immunology and Pharmaceutical Science**

Introduction

Deborah A. Eppstein is an accomplished inventor based in Menlo Park, California, recognized for her significant contributions to the fields of immunology and pharmaceutical science. With a remarkable portfolio of 15 patents, she is at the forefront of innovative solutions aimed at improving healthcare outcomes.

Latest Patents

Eppstein's latest patents demonstrate her commitment to advancing medical science. These include inventions related to N-[1, (1-1)-dialkyloxy] and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and their applications. Additionally, she has developed compounds featuring a dodecapeptide fragment A-(SEQ ID No: 1)-B, which corresponds to residues 174 to 185 of C-reactive protein (CRP). These compounds possess immunomodulatory activity and are integral to pharmaceutical compositions aimed at cancer treatment. Notably, Eppstein has explored the enhanced efficacy of liposomal formulations containing the CRP-peptide fragment, especially when used in conjunction with interleukin-2.

Career Highlights

Throughout her career, Deborah Eppstein has made a name for herself by working at prominent companies, including Syntex (U.S.A.) Inc. Her work has positioned her as a leader in the development of innovative treatments, particularly in immunology.

Collaborations

Eppstein has collaborated with notable colleagues such as Philip L. Felgner and Thomas R. Gadek. These collaborations have enabled her to expand her research horizons and contribute to significant advancements in the medical field.

Conclusion

Deborah A. Eppstein exemplifies the spirit of innovation in science and medicine. With her extensive patent portfolio and impactful contributions to immunology, she continues to inspire future generations of inventors and researchers dedicated to improving healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…